NHS (Neuberger Berman High Yield Strategies Fund) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NHS Neuberger Berman High Yield Strategies Fund Inc NHS
44 GF Score
Price $6.13
GF Value $7.23
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neuberger Berman High Yield Strategies Fund Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Neuberger Berman High Yield Strategies Fund Quality Rank Related Terms

NHS
44GF Score
Neuberger Berman High Yield Strategies Fund Inc NHS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuberger Berman High Yield Strategies Fund (NHS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuberger Berman High Yield Strategies Fund stock appears to be undervalued. The current stock price of $6.13 is trading 15.2% below its estimated GF Value™ of $7.23. GuruFocus considers Neuberger Berman High Yield Strategies Fund to be Modestly Undervalued.

Key valuation signals for NHS:

  • Quality Rank:
  • GF Value™: $7.23 vs. price of $6.13 (15.2% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the NHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuberger Berman High Yield Strategies Fund Business Description

Address c/o Neuberger Berman Investment Advisers LLC, 1290 Avenue of the Americas, New York, NY, USA, 10104-0002
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
44GF Score

Get the complete analysis for NHS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.13
Price
$7.23
GF Value